Rituximab in refractory autoimmune bullous diseases

Clinical and Experimental Dermatology

Volumn 31, Issue 4, 2006, Pages 503-508

  Schmidt, E ^a   Hunzelmann, N ^b   Zillikens, D ^c   Brocker E B ^a   Goebeler, M ^d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AUTOANTIBODY; AZATHIOPRINE; CD20 ANTIBODY; CLEMASTINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DESMOGLEIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RANITIDINE; RITUXIMAB; THEOPHYLLINE;

ANAPHYLAXIS; AUTOIMMUNE SKIN DISEASE; AUTOIMMUNITY; BACTERIAL ARTHRITIS; BACTERIAL PNEUMONIA; BULLOUS SKIN DISEASE; CHILL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; EPIDERMOLYSIS BULLOSA ACQUISITA; FEVER; HEADACHE; HUMAN; HYPOGAMMAGLOBULINEMIA; HYPOTENSION; IMMUNOADSORPTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PEMPHIGOID; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURITUS; REVIEW; SEPSIS; URTICARIA;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; IMMUNOLOGIC FACTORS; PEMPHIGOID, BULLOUS; PEMPHIGUS; SKIN DISEASES, VESICULOBULLOUS;

EID: 33744500477     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2006.02151.x     Document Type: Review

References (27)

1. Goebeler M, Sitaru C, Zillikens D. Bullous autoimmune disorders: Therapy. J Dtsch Dermatol Ges 2004 2 : 774 93.
2. Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother 2004 58 : 299 309.
3. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 1998 48 : 125 32.
4. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005 24 : 2121 43.
5. Quartier P, Brethon B, Philippet P et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001 358 : 1511 13.
6. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 350 : 2572 81.
7. Anolik JH, Campbell D, Felgar RE et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003 48 : 455 9.
8. Hertl M, Veldman C. T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun Rev 2003 2 : 278 83.
9. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004 50 : 2580 9.
10. Heizmann M, Itin P, Wernli M et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001 66 : 142 4.
11. Borradori L, Lombardi T, Samson J et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20 (+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001 137 : 269 72.
12. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2003 2 : 564 7.
13. Rossum MM, Verhaegen NT, Jonkman MF et al. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities. Leuk Lymphoma 2004 45 : 2327 32.
14. Szabolcs P, Reese M, Yancey KB et al. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 2002 30 : 327 9.
15. Schmidt E, Benoit S, Bröcker EB et al. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 2006 142 : 147 50.
16. Dupuy A, Viguier M, Bedane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004 140 : 91 6.
17. Kong HH, Prose NS, Ware RE, Hall RP 3rd. Successful treatment of refractory childhood Pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 2005 22 : 461 4.
18. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 2003 28 : 366 8.
19. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003 148 : 602 3.
20. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004 51 : 817 9.
21. Arin MP, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005 153 : 620 5.
22. Goebeler M, Herzog S, Bröcker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003 149 : 899 901.
23. Espana A, Fernandez-Galar M et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004 50 : 974 6.
24. Schmidt E, Herzog S, Bröcker EB, Zillikens D, Goebeler M. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005 153 : 449 51.
25. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002 47 : 785 8.
26. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases: successful result in refractory pemphigus vulgaris. Report of a case. Haematologica 2003 88 : ELT24.
27. Wenzel J, Bauer R, Bieber T, Tüting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol 2005 85 : 185 6.